Liminal BioSciences Inc. (LMNL)
Price:
8.50 USD
( + 0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
NEWS
LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
prnewswire.com
2023-09-26 08:00:00LAVAL, QC and CAMBRIDGE, England , Sept. 26, 2023 /PRNewswire/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") is pleased to announce that the transaction contemplated by the previously announced statutory plan of arrangement under the provisions of the Canada Business Corporations Act involving the Corporation and Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd.
LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
prnewswire.com
2023-09-19 16:22:00LAVAL, QC and CAMBRIDGE, England , Sept. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the Ontario Superior Court of Justice (Commercial List) approving the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd.
LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
prnewswire.com
2023-09-15 11:29:00LAVAL, QC and CAMBRIDGE, England , Sept. 15, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that its shareholders have approved the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd.
LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR
prnewswire.com
2023-09-12 07:45:00LAVAL, QC and CAMBRIDGE, England , Sept. 12, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced that an amendment to the previously filed Schedule 13E-3 will be filed to address comments raised by the Securities and Exchange Commission ("SEC") in connection with the previously announced plan of arrangement involving the acquisition by Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd.
LIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LP
prnewswire.com
2023-08-16 16:46:00LAVAL, QC and CAMBRIDGE, England , Aug. 16, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Ontario Superior Court of Justice (Commercial List) (the "Court") has issued an interim order (the "Interim Order") in connection with the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Plan of Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates (the "Minority Shares") at a price of US$8.50 per Share, payable in cash (the "Arrangement").
Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder
zacks.com
2023-07-13 12:36:14If the minority shareholders of Liminal BioSciences (LMNL) accept the buyout offer, they will receive $8.50 per share. This offer is a dollar more than the initial proposal received by management in April.
Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Management
marketwatch.com
2023-07-12 07:48:00Liminal BioSciences Inc. LMNL, -1.33% stock is rallying 41.7% in premarket trades on Wednesday after the company said it agreed to go private at a price of $8.50 a share. Structured Alpha LP, a fund managed by Thomvest Asset Management Ltd.
Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP
prnewswire.com
2023-07-12 07:30:00Liminal BioSciences minority shareholders to receive US$8.50 in cash per share in "go private" transaction LAVAL, QC, CAMBRIDGE, England, and TORONTO , July 12, 2023 /PRNewswire/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") (NASDAQ: LMNL) and Structured Alpha LP ("SALP"), a fund managed by Thomvest Asset Management Ltd., today announced that they have entered into a definitive arrangement agreement (the "Arrangement Agreement") under which SALP will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Common Shares") that it does not already own.
Why Is Liminal Biosciences (LMNL) Stock Up 77% Today?
investorplace.com
2023-04-05 10:56:47Liminal Biosciences (NASDAQ: LMNL ) stock is taking off on Wednesday as investors react to the biopharmaceutical company getting an unsolicited transaction proposal. According to a press release from the company, Structured Alpha LP is seeking to acquire Liminal Biosciences for $7.50 per share.
Liminal Biosciences' stock soars 91% after getting takeover offer that's more than double its price
marketwatch.com
2023-04-05 08:08:00Liminal Biosciences Inc.'s stock LMNL, -4.23% soared 91% in premarket trade Wednesday, after the company said it's received an unsolicited takeover offer of $7.50 a share from Structured Alpha LP. That company already owns 64% of the outstanding stock and is now bidding for the rest.
Liminal BioSciences Inc. (LMNL) Q4 2022 Earnings Call Transcript
seekingalpha.com
2023-03-17 16:08:04Liminal BioSciences Inc. (NASDAQ:LMNL ) Q4 2022 Results Conference Call March 16, 2023 8:30 AM ET Company Participants Shrinal Inamdar - IR Bruce Pritchard - CEO Nicole Rusaw - CFO Conference Call Participants Antonia Borovina - Bloom Burton Operator Good morning, ladies and gentlemen, and welcome to the Liminal BioSciences, Inc. Fourth Quarter 2022 Results [Foreign Language] Conference Call. [Operator Instructions] This call is being recorded on Thursday, March 16, 2023.
Liminal BioSciences to Present at BIO CEO & Investor Conference
prnewswire.com
2023-01-19 16:38:00LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Tuesday February 7, 2023 at 10:30am (ET) during the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023. The Company will be available for meetings with conference attendees.
Liminal Biosciences (LMNL) Q3 2022 Earnings Call Transcript
seekingalpha.com
2022-11-13 22:17:02Liminal Biosciences (NASDAQ:LMNL ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Chief Financial Officer Operator Good day and welcome to the Liminal Biosciences Third Quarter 2022 Results conference call. At this time, I would like to turn the call over to Shrinal.
Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights
headlinesoftoday.com
2022-08-09 17:07:00$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras development Net loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared to $12.6 million during the quarter ended June 30, 2021 LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2022 /PRNewswire/ – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal […]...
Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-05-13 15:22:12Liminal BioSciences Inc. (NASDAQ:LMNL ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Interim Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Operator Good day and welcome to the Liminal BioSciences, Inc. First Quarter 2022 Results Conference Call.
Liminal Biosciences to Present at Upcoming Investor Conferences
prnewswire.com
2022-05-09 08:30:00LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at the following upcoming investor conferences: H.C. Wainwright Global Investment Conference on Tuesday 24th May at 2:30-3:00 PM (EDT).
No data to display
LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
prnewswire.com
2023-09-26 08:00:00LAVAL, QC and CAMBRIDGE, England , Sept. 26, 2023 /PRNewswire/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") is pleased to announce that the transaction contemplated by the previously announced statutory plan of arrangement under the provisions of the Canada Business Corporations Act involving the Corporation and Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd.
LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
prnewswire.com
2023-09-19 16:22:00LAVAL, QC and CAMBRIDGE, England , Sept. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the Ontario Superior Court of Justice (Commercial List) approving the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd.
LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
prnewswire.com
2023-09-15 11:29:00LAVAL, QC and CAMBRIDGE, England , Sept. 15, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that its shareholders have approved the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd.
LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR
prnewswire.com
2023-09-12 07:45:00LAVAL, QC and CAMBRIDGE, England , Sept. 12, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced that an amendment to the previously filed Schedule 13E-3 will be filed to address comments raised by the Securities and Exchange Commission ("SEC") in connection with the previously announced plan of arrangement involving the acquisition by Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd.
LIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LP
prnewswire.com
2023-08-16 16:46:00LAVAL, QC and CAMBRIDGE, England , Aug. 16, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Ontario Superior Court of Justice (Commercial List) (the "Court") has issued an interim order (the "Interim Order") in connection with the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Plan of Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates (the "Minority Shares") at a price of US$8.50 per Share, payable in cash (the "Arrangement").
Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder
zacks.com
2023-07-13 12:36:14If the minority shareholders of Liminal BioSciences (LMNL) accept the buyout offer, they will receive $8.50 per share. This offer is a dollar more than the initial proposal received by management in April.
Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Management
marketwatch.com
2023-07-12 07:48:00Liminal BioSciences Inc. LMNL, -1.33% stock is rallying 41.7% in premarket trades on Wednesday after the company said it agreed to go private at a price of $8.50 a share. Structured Alpha LP, a fund managed by Thomvest Asset Management Ltd.
Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP
prnewswire.com
2023-07-12 07:30:00Liminal BioSciences minority shareholders to receive US$8.50 in cash per share in "go private" transaction LAVAL, QC, CAMBRIDGE, England, and TORONTO , July 12, 2023 /PRNewswire/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") (NASDAQ: LMNL) and Structured Alpha LP ("SALP"), a fund managed by Thomvest Asset Management Ltd., today announced that they have entered into a definitive arrangement agreement (the "Arrangement Agreement") under which SALP will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Common Shares") that it does not already own.
Why Is Liminal Biosciences (LMNL) Stock Up 77% Today?
investorplace.com
2023-04-05 10:56:47Liminal Biosciences (NASDAQ: LMNL ) stock is taking off on Wednesday as investors react to the biopharmaceutical company getting an unsolicited transaction proposal. According to a press release from the company, Structured Alpha LP is seeking to acquire Liminal Biosciences for $7.50 per share.
Liminal Biosciences' stock soars 91% after getting takeover offer that's more than double its price
marketwatch.com
2023-04-05 08:08:00Liminal Biosciences Inc.'s stock LMNL, -4.23% soared 91% in premarket trade Wednesday, after the company said it's received an unsolicited takeover offer of $7.50 a share from Structured Alpha LP. That company already owns 64% of the outstanding stock and is now bidding for the rest.
Liminal BioSciences Inc. (LMNL) Q4 2022 Earnings Call Transcript
seekingalpha.com
2023-03-17 16:08:04Liminal BioSciences Inc. (NASDAQ:LMNL ) Q4 2022 Results Conference Call March 16, 2023 8:30 AM ET Company Participants Shrinal Inamdar - IR Bruce Pritchard - CEO Nicole Rusaw - CFO Conference Call Participants Antonia Borovina - Bloom Burton Operator Good morning, ladies and gentlemen, and welcome to the Liminal BioSciences, Inc. Fourth Quarter 2022 Results [Foreign Language] Conference Call. [Operator Instructions] This call is being recorded on Thursday, March 16, 2023.
Liminal BioSciences to Present at BIO CEO & Investor Conference
prnewswire.com
2023-01-19 16:38:00LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Tuesday February 7, 2023 at 10:30am (ET) during the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023. The Company will be available for meetings with conference attendees.
Liminal Biosciences (LMNL) Q3 2022 Earnings Call Transcript
seekingalpha.com
2022-11-13 22:17:02Liminal Biosciences (NASDAQ:LMNL ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Chief Financial Officer Operator Good day and welcome to the Liminal Biosciences Third Quarter 2022 Results conference call. At this time, I would like to turn the call over to Shrinal.
Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights
headlinesoftoday.com
2022-08-09 17:07:00$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras development Net loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared to $12.6 million during the quarter ended June 30, 2021 LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2022 /PRNewswire/ – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal […]...
Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-05-13 15:22:12Liminal BioSciences Inc. (NASDAQ:LMNL ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Interim Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Operator Good day and welcome to the Liminal BioSciences, Inc. First Quarter 2022 Results Conference Call.
Liminal Biosciences to Present at Upcoming Investor Conferences
prnewswire.com
2022-05-09 08:30:00LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at the following upcoming investor conferences: H.C. Wainwright Global Investment Conference on Tuesday 24th May at 2:30-3:00 PM (EDT).